Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well...
Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well...
Organon已擴大其與Eli Lilly的協議，成爲偏頭痛藥物Emgality（Galcanezumab）在其他市場的唯一分銷商和推廣者，對Lilly的總代價包括一筆預付款2250萬美元。
Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well As Sales-based Milestone Payments
Organon已經擴大了與Eli Lilly的協議，成爲偏頭痛藥物Emgality（Galcanezumab）在其他市場的唯一分銷商和推廣商。對Lilly支付的總考慮包括前期支付2250萬美元以及基於銷售里程碑的支付。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。